P D F - S E A R C H

Page 1. Нашёл 853 ответа for 'Ecallantide'.

MG_Kalbitor_ecallantide.pdf
Kalbitor® (ecallantide). Last Review Date: October 14, 2019. Kalbitor (ecallantide) is considered medically necessary for the treatment of acute attacks of hereditary angioedema when the following...

https://www.emblemhealth.com/content/dam/emblemhealth/pdfs/provider/medical_policies/k/MG_Kalbitor_ecallantide.pdf

Last Review Status/Date
Description Kalbitor (ecallantide). Background. Kalbitor is a human plasma kallikrein inhibitor for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).

https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/-/media/pdfs/medical%20policies/09-24-19/58507%20kalbitor%20ecallantide.pdf

Kalbitor, INN-ecallantide
The ecallantide in Kalbitor is produced by a method known as ‘recombinant DNA technology’. This means that it is made by a cell that has received a gene (DNA), which makes the cell able to produce it.

https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-marketing-authorisation-application-kalbitor_en.pdf

Dyax s.a. withdraws its marketing authorisation application for Kalbitor...
The European Medicines Agency has been formally notified by Dyax s.a. of its decision to withdraw its application for a centralised marketing authorisation for the medicine Kalbitor (ecallantide), 10 mg/ml...

https://www.ema.europa.eu/en/documents/press-release/dyax-sa-withdraws-its-marketing-authorisation-application-kalbitor-ecallantide_en.pdf

Ecallantide
Ecallantide, a recombinant protein that acts as a reversible inhibitor of kallikrein, is currently indicated for acute attacks of HAE in those aged $12 years. In two randomized, double-blind, placebo-controlled...

https://www.researchgate.net/publication/275664236_Management_of_acute_attacks_of_hereditary_angioedema_Role_of_ecallantide/fulltext/5548158e0cf2b0cf7acead9a/Management-of-acute-attacks-of-hereditary-angioedema-Role-of-ecallantide.pdf

Pharmacotherapy for Angiotensin-Converting Enzyme...
ecallantide vs placebo among patients. Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter, randomized, controlled trial.

https://www.researchgate.net/profile/Ashwin_Ananth/publication/320958242_Pharmacotherapy_for_Angiotensin-Converting_Enzyme_Inhibitor-Induced_Angioedema_A_Systematic_Review/links/5bb14bdc92851ca9ed331c1d/Pharmacotherapy-for-Angiotensin-Converting-Enzyme-Inhibitor-Induced-Angioedema-A-Systematic-Review.pdf

C1 Esterase Inhibitor RUCONEST National Drug Monograph June 2015
In addition, two other treatments are available for acute HAE (ecallantide, icatibant). There are no direct comparison trials, and the different methods and instruments used to evaluate treatment...

https://www.pbm.va.gov/PBM/clinicalguidance/drugmonographs/C1_Inhibitor_RUCONEST_Monograph.pdf

Icatibant FIRAZYR National Drug Monograph June 2012
Ecallantide 30 mg SC vs. placebo. C1 INH 10 or 20 units/kg IV vs. placebo. Comparison continued. Icatibant (FIRAZYR). Ecallantide (KALBITOR). C1 Inhibitor (BERINERT).

https://www.pbm.va.gov/PBM/clinicalguidance/drugmonographs/Icatibant_FIRAZYR_Monograph.pdf

Icatibant (FIRAZYR®) - Angiotensin-Converting Enzyme Inhibitor...
ecallantide compared to conventional therapy that did not find a statistically significant difference in the percent improvement in patients receiving ecallantide.8,9 The authors stated that additional data are...

https://www.pbm.va.gov/PBM/clinicalguidance/drugmonographs/Icatibant_Monograph_Addendum.pdf

Icatibant Ecallantide
Summary Double-blind placebo-controlled trials were only found for ecallantide and icatibant. Both treatments did not show superiority over conventional treatment with histamine receptor antagonists...

https://link.springer.com/content/pdf/10.1007%2Fs40521-019-0203-y.pdf